New Delhi: Homegrown pharma major Cipla Ltd on Monday said it has acquired brand name and trademark rights for Vysov for anti-diabetic drug Vildagliptin for the Indian market from Novartis.
However, it didn't disclose the acquisition amount.
Cipla has been co-marketing Vildagliptin in agreement with Novartis under brand names Vysov and Vysov M (Vildagliptin plus Metformin), the company said in a regulatory filing.
"Owing to the increased affordability of Vildagliptin it is more accessible for better management of the disease. Cipla's acquisition of the trademark rights of Vysov will enable us to contribute to easier access of the drug in India," Cipla Executive Vice-President & Head India Business Nikhil Chopra said.
The products have witnessed a strong uptake in India for the last couple of years and are currently available across the country, the company said.
Vildagliptin is backed by strong clinical data and is therefore a widely prescribed antidiabetic medicine for adults with type-2 diabetes mellitus, it added
The market size of Vildagliptin in India is ₹818 crore as per IQVIA MAT data of November 2019, Cipla said.
This story has been published from a wire agency feed without modifications to the text. Only the headline has been changed.